Key result
Vasopressin infusion stabilizes hemodynamics and reduces LVOTO in refractory systolic anterior motion.
Why the study?
Managing left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve can be challenging, particularly during circulatory shock and pulmonary edema following cardiac surgery.
Vasopressin may be an effective and preferred vasopressor for managing left ventricular outflow tract obstruction and systolic anterior motion post-cardiac surgery due to its lack of inotropic effects.
BACKGROUND: Managing left ventricular outflow tract obstruction (LVOTO) and systolic anterior motion (SAM) of the mitral valve can be challenging, especially in the context of circulatory shock and pulmonary edema post cardiac surgery. CASE SUMMARY: We describe a case of an 80-year-old female patient with a history of severe aortic stenosis and hypertrophic obstructive cardiomyopathy that underwent aortic valve replacement and myectomy. The patient presented with acute pulmonary edema and low blood pressure due to LVOTO and SAM post cardiac surgery in the intensive care unit. She was paced with an epicardial dual-chamber pacing system due to complete atrioventricular block and treated initially with norepinephrine, furosemide, and esmolol infusion and continuous positive pressure ventilation. The patient remained hypoxemic and kept deteriorating hemodynamically despite titrating up norepinephrine. The addition of vasopressin infusion and tapering of norepinephrine finally stabilized the patient with significant reduction of LVOTO, confirmed by transthoracic echocardiography assessment, improved oxygenation and increased urine output. CONCLUSION: Vasopressin seems to be the preferred vasopressor for managing LVOTO and SAM post-cardiac surgery, because of its absence of inotropic effects. Echocardiography is crucial for early diagnosis and therapeutic management.
No takes yet. Share an insight, caveat, or question.
Elaiopoulos et al. (2025) conducted a review in Hypertrophic cardiomyopathy (HCM) with systolic anterior motion (SAM). Management strategies for SAM in HCM was evaluated. The pathophysiology of systolic anterior motion in hypertrophic cardiomyopathy involves drag forces and anatomic abnormalities, which can be managed with medical therapy, septal reduction, or mitral valve surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: